OBJECTIVE: Pregnancy is accompanied by dramatic physiological changes in maternal plasma proteins. Characterization of the maternal plasma proteome in normal pregnancy is an essential step for understanding changes to predict pregnancy outcome. The objective of this study was to describe maternal plasma proteins that change in abundance with advancing gestational age and determine biological processes that are perturbed in normal pregnancy. STUDY DESIGN: A longitudinal study included 43 normal pregnancies that had a term delivery of an infant who was appropriate for gestational age without maternal or neonatal complications. For each pregnancy, 3 to 6 maternal plasma samples (median, 5) were profiled to measure the abundance of 1125 proteins using multiplex assays. Linear mixed-effects models with polynomial splines were used to model protein abundance as a function of gestational age, and the significance of the association was inferred via likelihood ratio tests. Proteins considered to be significantly changed were defined as having the following: (1) >1.5-fold change between 8 and 40 weeks of gestation; and (2) a false discovery ratee adjusted value of P < .1. Gene ontology enrichment analysis was used to identify biological processes overrepresented among the proteins that changed with advancing gestation. RESULTS: The following results were found: (1) Ten percent (112 of 1125) of the profiled proteins changed in abundance as a function of gestational age; (2) of the 1125 proteins analyzed, glypican-3, sialic acid-binding immunoglobulin-type lectin-6, placental growth factor, C-C motif-28, carbonic anhydrase 6, prolactin, interleukin-1 receptor 4, dualspecificity mitogen-activated protein kinase 4, and pregnancyassociated plasma protein-A had more than a 5-fold change in abundance across gestation (these 9 proteins are known to be involved in a wide range of both physiological and pathological processes, such as growth regulation, embryogenesis, angiogenesis immunoregulation, inflammation etc); and (3) biological processes associated with protein changes in normal pregnancy included defense response, defense response to bacteria, proteolysis, and leukocyte migration (false discovery rate, 10%). CONCLUSION: The plasma proteome of normal pregnancy demonstrates dramatic changes in both the magnitude of changes and the fraction of the proteins involved. Such information is important to understand the physiology of pregnancy and the development of biomarkers to differentiate normal vs abnormal pregnancy and determine the response to interventions.
V iviparity requires major adaptations in the mother to sustain the establishment, development, growth, and eventual separation of a fetal semiallograft at the time of parturition. Pregnancy in placental mammals is a unique biological phenomenon, perhaps unmatched in the history of evolutionary biology. Reproductive success depends on an intensive and rich dialogue among mother, placenta, and fetus. The adaptations required for pregnancy appear to involve virtually all maternal organs/systems, including the metabolic/endocrinal, [1] [2] [3] [4] [5] [6] cardiovascular, [7] [8] [9] [10] [11] [12] respiratory, 13,14 gastrointestinal, 12, 15 hematological, 16, 17 and central nervous systems. 18, 19 The study of the physiology of pregnancy has spanned decades and has largely depended upon available technological capabilities to study parameters that change with gestational age. Such parameters have been studied with relatively simple methods, such as hormonal determinations, [20] [21] [22] concentrations of nutrients/fuels (glucose, [23] [24] [25] lipids, [26] [27] [28] [29] [30] [31] proteins, [32] [33] [34] [35] [36] [37] [38] and amino acids [39] [40] [41] ), blood pressure, 8, 42 cardiovascular function, 9, 11 spirometry, 13, 14 immunological assays, [43] [44] [45] and different tests of central nervous system functions. 18, 19 These studies have been essential to understanding changes in body composition, 4, 25 physiological adaptation, 10 ,14 the pathophysiology of selected pregnancy complications, 23, [46] [47] [48] and even postpartum adaptations (i.e. postpartum depression). [49] [50] [51] Most of these studies were designed and executed by looking at a separate organ system, as simultaneous and multidimensional studies were difficult to perform, analyze, and integrate. [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] One of the domains of interest that has proven to be extraordinarily successful is the study of changes in plasma protein concentrations in maternal blood. For example, the detection of human chorionic gonadotrophin (hCG) in human blood has allowed the early detection of pregnancy, even before the first signs of amenorrhea. [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] Monitoring early pregnancy with serial determinations of hCG has also allowed the identification of patients at risk for ectopic gestation and other forms of pregnancy failure. 79 In the case of ectopic pregnancy, this has allowed not only earlier diagnosis but also the introduction of minimally invasive surgical techniques (eg, laparoscopic resection and medical treatment). [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] The monitoring of gestational trophoblastic disease has also been dramatically changed with the use of serial hCG determinations in maternal serum/ plasma. [94] [95] [96] [97] [98] [99] However, these examples represent only the first of many diagnostic advances made possible by monitoring concentrations of a single protein during pregnancy.
The observation that a fetus with a neural tube defect had been born to a mother with an idiopathic elevation of maternal serum alpha fetoprotein [100] [101] [102] [103] eventually led to the discovery that such elevations could be used to screen for the presence of neural tube defects in the midtrimester of pregnancy and continue to be the basis, more than 20 years later, for the biochemical screening of these congenital anomalies. [104] [105] [106] [107] [108] [109] [110] [111] Further advances occurred with the introduction of the triple (followed by the quadruple) biochemical screening, including 3 proteins (alpha fetoprotein, hCG, inhibin), which were subsequently combined with a steroid hormone, estriol, to assess the likelihood of trisomies 18 and 21 at the end of the first trimester. 106, 107, [111] [112] [113] [114] [115] [116] [117] [118] Collectively, this evidence, now useful in routine clinical practice, provides compelling confirmation that examination of the plasma/ serum composition can offer important insight into the biology of pregnancy, fetal health, and disease; importantly, it has changed the practice of obstetrics and medicine.
The most recent entry into the protein biomarker discovery panel is the determination of angiogenic/anti-angiogenic factors for the early prediction of preterm preeclampsia, 47, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] fetal death, 129, 130 late preeclampsia, 47, [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] small-for-gestational-age (SGA), 131 and maternal floor infarction. 127, 132, 133 This set of biomarkers can now be readily determined using commercially available tests; it also has the potential to identify patients at risk for pregnancy complications in the long subclinical phase of the "great obstetrical syndromes" and to open the door for prevention, which has been a challenge in obstetrics for decades. 123, [134] [135] [136] [137] [138] [139] High -dimensional biology techniques  allow  characterization  of  the  genome,  54,55,140,141 transcriptome,   55,142-152 proteome, 55, 140, 142, [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] lipidome, [163] [164] [165] metabolome, 6, 55, 143, [166] [167] [168] [169] [170] [171] and cytome. [172] [173] [174] [175] The major thrust of the new biology and medicine has been to gather the information derived from these platforms to optimize diagnosis, prognosis, and treatment. 67, 176 Although each of these techniques has a particular informational domain (DNA, RNA, proteins, metabolites, lipids, etc.), they can be used independently or in combination. 66, 177 Proteins are considered to be important executors of biological functions, as they include enzymes, 178 structural components of tissues/cells, 56 the coagulation cascade, 179, 180 and the inflammatory network. 181 There have been substantial attempts to characterize the human plasma proteome in nonpregnant subjects, which have been made possible by the development of sophisticated mass spectrometry techniques, using a top-down approach. 62, 155, 182 These efforts have been extended to the maternal plasma proteome and amniotic fluid; 64, [153] [154] [155] 160, 162 however, technological complexities continue to challenge the goal of developing a comprehensive map of the entire human plasma proteome. The total estimated number of proteins in the human body ranges from 20,000 to 1 million; 183 of these, plasma proteome studies detected and semi-quantified a number between 16,500 to 20,000. 60, 63, 65, 184 Immunoassays and related methods continue to be the gold standard for the sensitive determination of proteins in peripheral plasma, guiding of diagnosis, monitoring of disease, and treatment; moreover, they are more sensitive than 2-dimensional gels or mass spectrometry and can detect analytes in very small quantities (below the nanomolar range). Nonetheless, these methods have a pitfall: they can be non-specific antibodies to non-conjugate proteins and macromolecules/micromolecules. Further, technologies, e.g., an enzymelinked immunosorbent assay (ELISA), require 2 antibodies to the same protein to elicit a signal. Such immunoassays cannot be multiplexed above a few tens of simultaneous measurement, largely because of the cross-reactivity of the secondary antibodies to surface-immobilized proteins. 57, 61, 185, 186 To enlarge the number of proteins that can be simultaneously detected with a high degree of sensitivity and dynamic range, a new technology not based on conventional antigen/antibody reaction has been developed. The aptamer-based method uses single-strand DNA or RNA molecules that bind with high affinity and specificity to proteins, peptides, or other pre-defined molecules. Recent publications emphasized the extraordinary potential of aptamer technology in biomarker discovery for cardiovascular disease 187 and other important biomedical disorders. [188] [189] [190] [191] [192] [193] [194] The objective of this study was to use aptamer-based technology to characterize the maternal plasma proteome of normal pregnancy as a function of gestational age. This study is important for the description of the simultaneous changes in plasma protein composition and will serve as the basis to detect departures of abnormalities before and during the time of diagnosis of major obstetrical complications.
Materials and Methods

Study design
We conducted a prospective longitudinal study that enrolled women with a normal pregnancy who attended the Center for Advanced Obstetrical Care and Research of the Perinatology Research Branch, the Detroit Medical Center, and Wayne State University. A retrospective cohort study was conducted to include 43 subjects who delivered at term, and 3 to 6 plasma samples were obtained from each during pregnancy before the spontaneous onset of labor [median number of samples, 5; interquartile range (IQR), [5] [6] . Plasma samples were collected during prenatal visits, scheduled at 4-week intervals from the first or early second trimester until delivery. At least 3 samples were collected from each patient during these gestational-age intervals: 8 to <16 weeks, 16 to <24 weeks, 24 to <28 weeks, 28 to <32 weeks, 32 to <37 weeks, and >37 weeks. The placenta was collected from each patient at the time of delivery, transported to the laboratory, and sectioned for histological examination, following the criteria of the Society for Perinatal Pathology. Lesions were diagnosed using previously established criteria. [195] [196] [197] Only patients without acute inflammatory lesions of the placenta were included in this study because of the potential to confound the relative abundance of the maternal plasma proteome. All patients provided written informed consent, and the use of biological specimens as well as clinical and ultrasound data for research purposes were approved by the Institutional Review Boards of Wayne State University and NICHD.
Proteomics technique
Maternal plasma protein abundance was determined using the Slow Off-rate Modified Aptamers (SOMAmer) platform and its reagents. This platform allows the measurement of more than 1125 proteins in maternal plasma samples. 186, 198, 199 Proteomics profiling was performed by Somalogic, Inc (Boulder, CO).
The serum samples were diluted and then incubated with the respective SOMAmer mixes preimmobilized onto streptavidin-coated beads. The beads were washed to remove all nonspecifically bound proteins and other matrix constituents. Proteins that remained specifically bound to their cognate SOMAmer reagents were tagged using an NHS-biotin reagent. After the labeling reaction, the beads were exposed to an anionic competitor solution that prevents nonspecific interactions from reforming after disruption.
Using this approach, pure cognateSOMAmer complexes and unbound (free) SOMAmer reagents are released from the streptavidin beads using ultraviolet light that cleaves the photocleavable linker used to quantitate protein. The photo-cleavage eluate, which contains all SOMAmer reagents (some bound to a biotin-labeled protein and some free), was separated from the beads and then incubated with a second streptavidin-coated bead that binds the biotin-labeled proteins and the biotinlabeled protein-SOMAmer complexes. The free SOMAmer reagents were then removed during subsequent washing steps. In the final elution step, proteinbound SOMAmer reagents were released from their cognate proteins using denaturing conditions. These SOMAmer reagents were then quantified by hybridization to custom DNA microarrays. The cyanine-3 signal from the SOMAmer reagent was detected on microarrays. 186, 198, 199 
Statistical analysis
Demographic data analysis Clinical characteristics of the patient population were summarized as median and interquartile ranges (IQR) for continuous variables or as percentages for categorical variables, using SPSS software (version 19; IBM Corp, Armonk, NY) ( Table 1) .
Differential abundance analysis
Protein abundance expressed as fluorescence units was log (base 2) transformed to improve normality. Linear mixed-effects models with cubic splines (number of knots ¼ 3) were used to model protein abundance as a function of gestational age using the lme4 package 200 under the R statistical language and environment (www.r-project. org). Inference about statistical significance of associations was calculated using likelihood ratio tests between a model that included the gestational age terms (fixed and corresponding random effects) and a simpler random intercept linear mixed-effects model without gestational age terms.
Protein abundance was considered to have changed significantly with gestational age if it met the following criteria: (1) the magnitude of abundance of change was >1.5-fold between 8 and 40 weeks of gestation; and (2) false discovery rate- 201 adjusted values (q-values) of P < .1. Similar or less stringent criteria have been extensively used in highdimensional biology and have shown good validation by alternative techniques and/or in independent sets of samples. [202] [203] [204] [205] Fold change was defined as the ratio of protein abundance (in relative fluorescence units) between the highest and lowest mean values across gestational age. The median (50th quantile) and 10th and 90th quantiles of the protein abundance were also determined using quantile regression modeling. 206, 207 In these models, the relationship between protein abundance was assumed to be linear within a narrow moving window of gestational age, and this allowed us to obtain a non-linear smooth estimate of the quantiles as previously described. 125 Clustering proteins by average profile To identify groups of proteins based on their pattern of change across gestation, we used unsupervised hierarchical clustering. The input in this analysis was the mean protein abundance across gestation (longitudinal patterns) computed from linear mixed-effects models for each gestational week from 8 to 40 weeks. Average profiles were scaled between 0 and 1 prior to applying hierarchical clustering with Euclidean distance so that proteins with similarity longitudinal patterns (eg, monotonically increasing) are grouped together despite eventual differences in the magnitude of change (eg, rate of increase) or overall protein abundance.
With hierarchical clustering, each protein is considered a cluster by itself, and iteratively, clusters are merged so that the distance between the farthest apart members of the clusters (complete linkage) is minimized. To determine the optimal number of clusters, we used a goodness-of-clustering measure (the gap statistic), which compares the change in within-cluster dispersion (sum of squared distances between cluster members) with that expected under the null distribution (simulated by bootstrap).
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Gene ontology enrichment analysis Having identified proteins that change in abundance as a function of gestational age, the next step was to gain an ajog.org OBSTETRICS Original Research understanding of the potential functional roles of these proteins in human pregnancy. To accomplish this, we relied on the information deposited for the gene encoding of each protein that has been organized in publicly available databases (ie, gene ontology). We focused on the biological processes in which these proteins have been implicated. Each protein was mapped to an identifier in the Entrez gene database 209 based on the Somalogic, Inc protein annotation system and then to gene ontology. 210 Biological processes overrepresented among the proteins changed in abundance with advancing gestational age. We used a Fisher's exact test and odds ratios to estimate enrichment. Gene ontology terms with 3 or more hits and an adjusted value of P < .1 were considered significantly enriched in gestational age-modulated proteins.
Protein-protein interaction network analysis
To explore the potential impact of gestation on human plasma proteins not profiled in this study, we conducted an in silico analysis for which we retrieved the known protein-protein map interactions from the publicly available Protein Reference Database (release 9) 211 using the NCBI2R package. For each of the 1125 proteins profiled, we determined the number of protein-protein interactions documented in the database. For visualization purposes, a graph was constructed linking proteins with known interactions with the 112 proteins changing with gestational age.
Results
Clinical characteristics of the study population
Forty-three women with normal pregnancies met the criteria for inclusion in this study. The median (IQR) maternal age was 25 (21e28) years old, and 88.4% of patients were of African-American origin by self-reporting. All patients delivered at term without any obstetrical complications and had neonates with an appropriate weight for gestational age. 212 The median gestational age at delivery was 39.4 ([IQR] 39.0e40.1) weeks.
Maternal plasma proteome in normal pregnancy characterized by Somascan
Ten percent of the proteins profiled (112 of 1125) changed in abundance as a function of gestational age (fold change >1.5 and value of Q < .1) (see Table 2 ). Figure 1 shows the longitudinal protein abundance for 2 selected proteins together with the fitted mean (by linearmixed effects models) and median (by quantile regression) as a function of gestation. Similar plots for all 112 significant proteins are displayed in Supplemental File 1.
Thirty-six percent (41 of 112) of proteins decreased in abundance and 64% (71 of 112) increased with gestational age. Hierarchical cluster analysis of average protein profiles across gestation (see Figure 2 ) demonstrated among the increasing abundant proteins 3 patterns in the change of the relative fluorescence reading (increasing rate: n ¼ 21, constant rate: n ¼ 23, and decreasing rate: n ¼ 27). Similar patterns were observed among proteins with decreasing abundance during gestation (increasing rate: n ¼ 8, constant rate: n ¼ 16, and decreasing rate: n ¼ 17).
The most highly modulated proteins (highest fold change) among the significant ones were as follows: (1) placental growth factor (PlGF); (2) pregnancyassociated plasma protein A (PAPP-A) (>5-fold change in abundance across gestation; (3) sialic acid-binding immunoglobulin-type lectins (Siglec)-6; (4) glypican-3; (5) C-C motif (CCL)-28; (6) carbonic anhydrase 6; (7) prolactin (PRL); (8) interleukin-1 receptor 4 (IL-1 R4); and (9) dual-specificity mitogenactivated protein kinase kinase 4 (MP2K4) (see Figure 3 ).
Biological processes modulated during gestation
Gene ontology analysis of the corresponding proteins that changed with gestational age revealed 14 biological processes impacted by advancing gestation. These biological processes included the following: general defense response, defense response to bacteria, defense response to fungi, germ cell migration, proteolysis, and leukocyte migration (false discovery rate, 10%) (see Table 3 ).
Of the 14 processes, defense response to fungus, germ cell migration, and defense response to bacteria indicated a decreased abundance of the protein associated with these biological processes as gestation advanced. In contrast, only the biological process of smooth muscle cell migration showed an increased abundance of its proteins.
Protein-protein interaction network
An analysis was performed to retrieve the known protein-protein interactions 
Comment
Principal findings of the study
The principal findings of the study are as follows: (1) Ten percent of the 1125 proteins assessed in this study of maternal plasma changed with advancing gestational age (112 of 1125); (2) the concentration of 9 proteins (PlGF, PAPP-A, Siglec-6, glypican-3, CCL-28, carbonic anhydrase 6, PRL, IL-1 R4, and dual-specificity MP2K4) increased dramatically in abundance (fold change >5); (3) proteins demonstrated either an increase or a decrease in abundance with advancing gestational age following at least 3 distinct patterns of change (increasing rate, constant rate, and decreasing rate of change in abundance); and (4) functional analysis revealed that the proteins identified as changing with gestational age belonged to the following biological processes (as determined by gene ontology-derived analysis methods): general defense response, defense response to bacteria, defense response to fungi, germ cell migration, proteolysis, and leukocyte migration. This communication reports changes in a large number of proteins in the maternal plasma proteome in normal pregnancy using a state-of-theart proteomic multiplex platform. The results in normal pregnancy reported herein can serve as the basis for the identification of biomarkers for the prediction, monitoring of disease, and diagnosis of obstetrical disorders.
Meaning of the study
The reasons to characterize the maternal plasma proteome in normal pregnancy have been outlined in the introduction of this paper, and the information derived from measuring protein concentrations has had great clinical value for the care of pregnant women.
We found 9 proteins that showed a dramatic increase in concentration, defined as more than 5-fold. The magnitude of change of PlGF was 14.5-fold, and this protein plays an important role in the control of angiogenesis, a key process in placental development. Low concentrations of PlGF have already been reported in patients who subsequently developed early onset [122] [123] [124] [125] maternal floor infarction, 127, 132, 133 mirror syndrome, 134, [217] [218] [219] [220] [221] and some forms of twin-to-twin transfusion syndrome. 222 The identification of PlGF as a protein that underwent dramatic changes in maternal plasma concentration in this study (and using current technologies) is reassuring, given its physiological importance as well as the prognostic value in measuring this concentration in maternal plasma to identify patients at risk for adverse pregnancy outcome.
The same applies to PAPP-A, one of the top 9 proteins whose concentration 
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The figure shows 3 clusters of proteins with increasing overall trends (increasing rate, n ¼ 21; constant rate, n ¼ 23; and decreasing rate, n ¼ 27) and 3 clusters with decreasing overall trends (increasing rate, n ¼ 8; constant rate, n ¼ 16; and decreasing rate, n ¼ 17). ajog.org OBSTETRICS Original Research increased more than 5-fold in this study. PAPP-A is mainly produced by the placenta, and its concentration is low in the first trimester of pregnancies complicated by either chromosomal abnormalities (trisomies 21, 18 and 13, and monosomy X) 111, [115] [116] [117] [118] [223] [224] [225] [226] [227] [228] or a subset destined to develop placentamediated obstetrical syndromes such as SGA and preeclampsia 136, 227, [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] and preterm birth. 241 In this study, we also report the longitudinal changes in the plasma concentrations of PAPP-A as a function of gestational age. The concentration of PAPP-A increased steadily until about 20 weeks of gestation, when it plateaued and remained relatively stable until term. Our observations are consistent with those of a previous report and provide further strength to the validity of our findings.
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Maternal plasma Siglec-6 and glypican-3 were also among the top-ranked proteins that increased in concentration with advancing gestational age 17-and 26-fold, respectively (Table 2) . Although these proteins were previously described in in vitro studies and nonpregnant subjects, there is no systematic study describing the changes in the concentrations of these proteins in maternal plasma in normal or abnormal pregnancy.
Siglec-6 is a CD33rSiglec that has been implicated in the regulation of 2 major biological functions: cell-to-cell interactions and regulation, through glycan recognition, of the innate and adaptive immune systems. [243] [244] [245] [246] This molecule can also serve as a leptin receptor (OB-BP1), which has high specificity and affinity to this molecule. Importantly, Siglec-6 is expressed only in cyto-and syncytiotrophoblasts of the human placenta, [247] [248] [249] and this may explain how it gains access to the maternal circulation and increases with gestational age as the volume of the villous tree increases. 247 A recent report documented an increase in Siglec-6 expression in the placenta following spontaneous labor and delivery in comparison to those following elective cesarean delivery without labor; therefore, it has been proposed that this molecule may play a role in the process of parturition. 247, 250 In addition, increased Siglec-6 trophoblast expression was reported in women with gestational trophoblastic disease and those with preterm preeclampsia. 249, [251] [252] [253] [254] The findings in Siglec-6 reported herein provide further support that an increase in abundance of this protein, detected with current technology in the maternal circulation, may have biological and clinical implications.
There is a paucity of information about glypican-3 in pregnancy. This protein is a heparan-sulfate proteoglycan that acts as a coreceptor for heparin-binding growth factors, such as insulin-like growth factor, [255] [256] [257] [258] [259] [260] [261] which is expressed in the syncytiotrophoblast of term placentas and has been reported to be down-regulated in the trophoblasts of patients with preeclampsia. 262, 263 One study reported a link between glypican-3 and one of the major anticoagulation proteins of the trophoblast-placenta protein 5/tissue factor pathway inhibitor 2: this anticoagulation protein is specific to pregnancy and has been implicated in the maintenance of placental hemostasis; the The figure shows protein abundance in log (base 2) relative fluorescence units computed from linear mixed-effects models with cubic splines. Average profiles were shifted so that the minimum expression corresponds to 0 for all proteins. The 9 most-changing proteins were (decreasing fold change order): glypican-3, Siglec-6: sialic acid-binding immunoglobulin-type lectins 6, PlGF: placental growth factor, CCL28: C-C motif 28, carbonic anhydrase 6, PRL: prolactin, IL-1 R4: interleukin-1 receptor 4, MP2K4: dual-specificity mitogen-activated protein kinase kinase 4, and PAPP-A: pregnancy-associated plasma protein A.
CCL28, C-C motif 28, carbonic anhydrase 6; IL-1 R4, interleukin-1 receptor 4; MP2K4, dual-specificity mitogen-activated protein kinase kinase 4; PAPP-A, pregnancy-associated plasma protein A; PlGF, placental growth factor; PRL, prolactin; Siglec-6, sialic acid-binding immunoglobulin-type lectins 6. placental expression of the latter is reduced in preeclampsia. 262 Glypican-3 has been proposed to serve as the anchoring protein of placenta protein 5/ tissue factor pathway inhibitor 2 and that the decrease in glypican-3 in preeclampsia leads to the release of placenta protein 5/tissue factor pathway inhibitor 2 into the maternal circulation, promoting a higher concentration in this obstetrical syndrome. Our study reports the first changes in the concentrations of glypican-3 in the maternal circulation, and it is noteworthy that this protein increases 26-fold during pregnancy in a pattern of decreasing slope (Figure 3 ) with advancing gestational age.
Several of the findings reported herein are consistent with those described in maternal plasma/serum for other proteins: this lends reassurance to the validity of our findings derived with the use of a novel aptamer-based technology. Specific examples include plasminogen activator inhibitor type 1, 264 insulin-like growth factor binding protein-1, 265-270 hepcidin, 271 and thyroid-stimulating hormone. 272 The current study is the first to examine and analyze longitudinally the profile of the maternal plasma proteome of more than 1000 proteins simultaneously using a highdimensional biology platform.
Biological processes modulated during gestation
Gene ontology analysis revealed that the defense response, proteolysis, and [273] [274] [275] [276] [277] [278] [279] [280] Tolerance of a semiallograft (fetus and placenta) represents a major biological challenge imposed by viviparity. While the fundamental mechanisms responsible for this remain to be elucidated, a general proposal is that there is a down-regulation of the specific limb of the adaptive immune response aimed at paternal antigens, with an up-regulation of the innate immune response. [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] Down-regulation of specific immune responses includes not only paternal/fetal antigens but also microbial products; therefore, the physiological modulation of the immune response to enhance tolerance of the semiallograft could expose the mother to infection, and the infectious process may be more severe. 292, 293 Evidence in support of this response indicates that patients with pyelonephritis during pregnancy are more likely to develop acute respiratory distress syndrome and other complications, [294] [295] [296] [297] [298] [299] and those with viral diseases during pregnancy (eg, influenza, varicella, H1N1, SARS) are more likely to develop serious complications and even die during pregnancy. [300] [301] [302] [303] [304] [305] [306] [307] [308] The production of antimicrobial peptides (AMP) is a mechanism to enhance host immunoprotection, and indeed, the production of a broad range of antimicrobial peptides (antibacterial and antiviral) is enhanced during pregnancy. [309] [310] [311] [312] [313] Such products have been detected in both the amniotic cavity and systemic circulation. [314] [315] [316] [317] The amniotic fluid is known to have antimicrobial properties, [317] [318] [319] [320] [321] [322] [323] and this could be due to the presence of naturally occurring AMPs, such as bactericidal/permeability-increasing protein, 312 The nature of the host immune response to microorganisms during pregnancy may not be uniform and may be context dependent. For example, there is some evidence that the host defense against fungi is not as robust as that against bacteria, and this may explain the increased predisposition to vaginal candidiasis during pregnancy. [332] [333] [334] [335] [336] Furthermore, patients who conceived with an intrauterine contraceptive device are particularly susceptible to infections with fungi in the amniotic cavity, and this may reflect unique features of the complex immune response to different microorganisms during pregnancy. [337] [338] [339] [340] [341] [342] [343] [344] [345] [346] [347] One of this study's findings indicates that proteins related to smooth muscle cell migration are increased in abundance in maternal plasma with advancing gestational age; this finding is entirely consistent with the fact that the uterus must grow during pregnancy to accommodate the increased size of the fetus, placenta, and amniotic fluid. Importantly, there has not been a good biomarker to monitor smooth muscle function in maternal plasma, and the findings in this study open the door for the identification of such proteins. Original Research OBSTETRICS ajog.org
Protein-protein interaction network
Proteins function in concert as a part of larger protein complexes within a cell; therefore, an important aspect of proteomic analysis lies in the elucidation of interacting proteins and mapping the corresponding binding sites. 348, 349 By identifying proteins interacting with those modulated during normal pregnancy, we can hypothesize on the importance of the change in protein abundance with gestation. These inferences rely on the basis of their degree (number of direct protein-protein interactions) in the interactome. Of note, the average number of interacting proteins in the Human Protein Reference Database is w3.7 per protein. 349 Protooncogene tyrosine-protein kinase Src (SRCN1) and Tyrosine-protein kinase Fyn (FYN) had 260 and 196 documented interactions in the Human Protein Reference Database; thus, these 2 proteins appear to play a central role in the interactome.
SRCN1 is part of the Src signaling system involved in cellular signaling of proteinase-activated receptor-2, that is, a G protein-coupled receptor that modulates activation induces vascular endothelial growth factor receptor (VEGFR)-1 promoter activity and soluble VEGFR-1 release from endothelial cells. Given the importance of VEGFR-1 in the regulation of endothelial function during pregnancy and its pathogenesis in preeclampsia, SGA, fetal death, maternal floor infarction, and some forms of spontaneous preterm labor, our findings strengthen the case for the importance of discovery techniques in the elucidation of fundamental mechanisms of disease in obstetrics.
FYN is also a member of the Src family. In contrast to SRCN1, FYN is involved in immune system activity, especially in T-cell signaling and animal models, suggesting an association with decreased fetal maternal tolerance through the regulation of Th17. In addition, animal experimentation has demonstrated that this protein is also involved in neuronal signaling, migration, and cortical development cell physiology.
350,351
Strengths and limitations
The study's major strength is the characterization of the maternal plasma proteome in longitudinal samples of patients who had a normal pregnancy outcome defined by clinical, neonatal, and pathologic examination of the placenta. We simultaneously examined a large number of proteins (>1000) using sensitive techniques that have been rigorously validated. This study represents the largest examination of the maternal plasma proteome during pregnancy. Another strength is the identification of proteins, such as PlGF and PAPP-A, previously found to be dramatically up-regulated during pregnancy, as well as the discovery of novel proteins that were not known to be drastically changed in concentration. The identification of 3 broad patterns of protein changes with a large number of proteins is also important, as these observations were not known with specificity prior to this study.
One limitation of this study is that the concentrations are expressed in relative fluorescence units, rather than absolute concentrations; hence, batch effects do not allow a direct comparison of the normal pregnancy reference intervals estimated in this study to data that will be obtained in future studies. However, departures of longitudinal patterns across gestation from the reference intervals we determined can enable the discovery of biomarkers unhindered by possible experimental biases. Such discoveries can be followed by the quantification gained from alternative protein measurement techniques such as immunoassays or mass spectrometry-based assays. In addition, the large majority of the patients included in this study were of African-American descent, and future studies will be required to determine whether the changes reported herein occur in populations of other ethnic groups.
Summary
This is the first comprehensive study to characterize the longitudinal maternal plasma proteome in pregnancy with the use of novel technology. Because the proteomics technique provided protein abundance measurements expressed in relative fluorescence units, we could not derive reference ranges of protein concentrations so that one can compare future data directly against these references. However, the patterns of change with gestation that we describe can still be useful in discovering disease markers in future studies, provided that they deviate from the expected trajectory, regardless of the baseline concentration, which may be subject to experimental batch effects. n
